Shopping Cart
Remove All
Your shopping cart is currently empty
NRPa-308
(Synonyms: NRPa308, NRPa 308) Copy Product Info
🥰Excellent
Synonyms: NRPa308, NRPa 308
Catalog No. T212932 Copy Product Info
Purity: 99.55%
🥰Excellent
NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model. NRPa-308 is used in angiogenesis and tumor biology research systems to investigate neuropilin-1-mediated vascular signaling, endothelial cell proliferation regulation, and tumor microenvironment modulation in xenograft cancer models.
NRPa-308
Cas No. 717863-53-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $78 | - | In Stock | |
| 5 mg | $189 | - | In Stock | |
| 10 mg | $283 | - | In Stock | |
| 25 mg | $569 | - | In Stock | |
| 50 mg | $858 | - | In Stock | |
| 100 mg | $1,280 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $198 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.55%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model. NRPa-308 is used in angiogenesis and tumor biology research systems to investigate neuropilin-1-mediated vascular signaling, endothelial cell proliferation regulation, and tumor microenvironment modulation in xenograft cancer models. |
| In vivo | Method: A series of 18 small organic VEGF-A165/NRP-1 antagonists were synthesized and tested in vitro for anti-angiogenic activity and effects on viability of human cancer cell lines. Result: Compound 2a (NRPa-308) showed potent anti-angiogenic activity in vitro and affected viability across a broad panel of human solid and hematological cancer cell lines. It exhibited lower cytotoxicity on healthy tissues compared with sunitinib in vitro. |
| Synonyms | NRPa308, NRPa 308 |
| Molecular Weight | 424.51 |
| Formula | C23H24N2O4S |
| Cas No. | 717863-53-1 |
| Smiles | O=C(NC=1C=CC=CC1OCC)C2=CC=C(C(=C2)S(=O)(=O)NC3=CC=C(C=C3)C)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (188.45 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: NRPa-308 in vivo | NRPa-308 formula | NRPa-308 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.